サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1655468

大腸がん治療の世界市場

Colorectal Cancer Therapeutics

出版日
ページ情報
英文 363 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
大腸がん治療の世界市場
出版日: 2025年02月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 363 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

大腸がん治療の世界市場は2030年までに223億米ドルに達する見込み

2024年に153億米ドルと推定される大腸がん治療の世界市場は、2024～2030年の分析期間においてCAGR 6.5%で成長し、2030年には223億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである標的療法は、CAGR7.1%を記録し、分析期間終了時には149億米ドルに達すると予測されます。免疫療法分野の成長率は、分析期間中CAGR 5.5%と推定されます。

米国市場は推定40億米ドル、中国はCAGR10.1％で成長予測

米国の大腸がん治療市場は2024年に40億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに54億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.1%と5.7%と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

世界の大腸がん治療市場- 主要動向と促進要因のまとめ

大腸がんが懸念される理由とは？

結腸と直腸のがんを含む大腸がんは、依然として世界的に大きな健康上の懸念となっています。大腸がんは男女ともに3番目に多く診断されるがんであり、罹患率および死亡率も高いです。危険因子としては、年齢、遺伝的素因、食事や運動不足などの生活習慣、炎症性腸疾患などが挙げられます。早期の大腸がんは、症状がほとんどないか全くないことが多く、早期発見のためには定期的なスクリーニングが重要です。スクリーニングには、大腸内視鏡検査、便潜血検査、画像診断が一般的に用いられているが、これらの予防手段へのアクセスや遵守状況は、集団によって大きく異なります。大腸がんの世界の罹患率は増加しており、特に欧米化したライフスタイルが浸透しつつある新興諸国では、ヘルスケアのインフラが症例の急増に対応しきれない可能性があります。

治療アプローチはどのように進化しているのか？

大腸がん治療の状況は、過去数十年の間に大きく進化してきました。手術、放射線療法、化学療法を含む伝統的な治療法は、大腸がん管理の要でした。手術は限局がんに対する主要な治療法であり、しばしば再発リスクを軽減するために補助化学療法が行われます。腹腔鏡手術やロボット手術の進歩により、治療成績は向上し、回復時間も短縮されました。化学療法レジメンも洗練され、FOLFOX（ロイコボリン、フルオロウラシル、オキサリプラチン）やFOLFIRI（ロイコボリン、フルオロウラシル、イリノテカン）などの薬剤併用療法は有効性が向上しています。さらに、放射線療法の技術は、健康な組織を温存しながら腫瘍をより正確に狙い撃ちし、副作用を最小限に抑えるように改良されてきました。

標的治療は治療においてどのような役割を果たすのか？

大腸がん治療における重要なトレンドは、がんの進行に関与する特定の分子経路を攻撃することを目的とした分子標的治療の出現です。血管内皮増殖因子（VEGF）を阻害するベバシズマブ（アバスチン）や、上皮増殖因子受容体（EGFR）を標的とするセツキシマブ（アービタックス）などのモノクローナル抗体は、転移性大腸がんの治療に大きな成功を示しています。もうひとつの画期的な進歩は、ペムブロリズマブ（キイトルーダ）やニボルマブ（オプジーボ）のような免疫チェックポイント阻害剤の開発で、マイクロサテライト不安定性高値（MSI-H）またはミスマッチ修復欠損（dMMR）大腸がんの治療に革命をもたらしました。これらの治療法は、がん細胞に対する身体の免疫反応を強化し、進行がん患者に新たな希望をもたらします。さらに、腫瘍の遺伝子および分子プロファイリングの調査により、個々の患者の特性や腫瘍生物学に基づいて治療法を調整する、より個別化された治療アプローチが可能になりつつあります。

大腸がん治療市場の成長を促進する要因は？

大腸がん治療市場の成長は、いくつかの要因によってもたらされます。主な促進要因の1つは、大腸がんの有病率の増加であり、高度な治療法の開発と導入が必要となっています。大腸がんのリスクが高い高齢者人口の拡大も市場成長に寄与しています。次世代シーケンシングや低侵襲手術手技など、診断・治療ツールの技術的進歩が治療成果を高め、市場の需要を促進しています。さらに、個人と腫瘍の遺伝子プロファイルに合わせて治療を調整する個別化医療の採用が増加していることも、治療状況を一変させています。新規の標的療法や免疫療法の承認と統合は、より効果的な治療選択肢を提供し、市場の大幅な拡大を促しています。製薬企業による研究開発への投資や、学術機関と業界各社による共同研究は、革新的な治療法の導入をさらに加速させています。さらに、認知度の向上と検診への取り組みが早期診断・早期治療につながり、生存率を向上させて市場成長を後押ししています。

セグメント

治療法（標的療法、免疫療法、化学療法、その他の治療法）;がんタイプ（大腸腺がん、消化管カルチノイド腫瘍、その他のがんタイプ）

調査対象企業の例（注目18社）

  • Amgen, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Merck KGaA
  • Novartis International AG
  • Spectrum Pharmaceuticals

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-1689

Global Colorectal Cancer Therapeutics Market to Reach US$22.3 Billion by 2030

The global market for Colorectal Cancer Therapeutics estimated at US$15.3 Billion in the year 2024, is expected to reach US$22.3 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.0 Billion While China is Forecast to Grow at 10.1% CAGR

The Colorectal Cancer Therapeutics market in the U.S. is estimated at US$4.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.4 Billion by the year 2030 trailing a CAGR of 10.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Colorectal Cancer Therapeutics Market - Key Trends and Drivers Summarized

What Makes Colorectal Cancer a Growing Concern?

Colorectal cancer, encompassing cancers of the colon and rectum, remains a major health concern globally. It is the third most common cancer diagnosed in both men and women, with significant morbidity and mortality rates. The risk factors include age, genetic predisposition, lifestyle factors such as diet and physical inactivity, and inflammatory bowel diseases. Early-stage colorectal cancer often presents with minimal or no symptoms, making routine screening critical for early detection. Colonoscopy, fecal occult blood tests, and imaging techniques are commonly used for screening, yet accessibility and adherence to these preventive measures vary widely across different populations. The global burden of colorectal cancer is rising, particularly in developing countries where westernized lifestyles are increasingly adopted, and healthcare infrastructure may be less equipped to handle the surge in cases.

How Are Therapeutic Approaches Evolving?

The landscape of colorectal cancer therapeutics has significantly evolved over the past decades. Traditional treatment modalities, including surgery, radiation therapy, and chemotherapy, have been the cornerstone of colorectal cancer management. Surgery remains the primary treatment for localized cancers, often followed by adjuvant chemotherapy to reduce recurrence risk. Advances in laparoscopic and robotic surgeries have improved outcomes and reduced recovery times. Chemotherapy regimens have also become more sophisticated, with combinations of drugs such as FOLFOX (leucovorin, fluorouracil, and oxaliplatin) and FOLFIRI (leucovorin, fluorouracil, and irinotecan) showing enhanced efficacy. Additionally, radiation therapy techniques have been refined to target tumors more precisely while sparing healthy tissue, minimizing side effects.

What Role Does Targeted Therapy Play in Treatment?

A significant trend in colorectal cancer treatment is the advent of targeted therapies, which aim to attack specific molecular pathways involved in cancer progression. Monoclonal antibodies such as bevacizumab (Avastin), which inhibits vascular endothelial growth factor (VEGF), and cetuximab (Erbitux), which targets the epidermal growth factor receptor (EGFR), have shown considerable success in treating metastatic colorectal cancer. Another breakthrough is the development of immune checkpoint inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo), which have revolutionized treatment for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancers. These therapies enhance the body's immune response against cancer cells, offering new hope for patients with advanced disease. Furthermore, research into genetic and molecular profiling of tumors is enabling more personalized treatment approaches, tailoring therapies based on individual patient characteristics and tumor biology.

What Factors Are Driving the Growth in the Colorectal Cancer Therapeutics Market?

The growth in the colorectal cancer therapeutics market is driven by several factors. One of the primary drivers is the increasing prevalence of colorectal cancer, necessitating the development and adoption of advanced treatment options. The expanding elderly population, who are at higher risk for colorectal cancer, also contributes to market growth. Technological advancements in diagnostic and therapeutic tools, such as next-generation sequencing and minimally invasive surgical techniques, are enhancing treatment outcomes and fueling market demand. Additionally, the rising adoption of personalized medicine, which tailors treatment to the genetic profile of the individual and their tumor, is transforming the therapeutic landscape. The approval and integration of novel targeted therapies and immunotherapies are providing more effective treatment options, driving significant market expansion. Investment in research and development by pharmaceutical companies and collaborations between academic institutions and industry players are further accelerating the introduction of innovative therapies. Moreover, increasing awareness and screening initiatives are leading to earlier diagnosis and treatment, improving survival rates and bolstering market growth.

SCOPE OF STUDY:

The report analyzes the Colorectal Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies); Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Other Cancer Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 18 Featured) -

  • Amgen, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Merck KGaA
  • Novartis International AG
  • Spectrum Pharmaceuticals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Colorectal Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Colorectal Cancer Throws the Spotlight on Therapeutics
    • Advances in Immunotherapy Propels Growth in Colorectal Cancer Therapeutics
    • Increasing Use of Personalized Medicine Expands Addressable Market Opportunity
    • Development of Targeted Therapies Strengthens Business Case for Colorectal Cancer Drugs
    • Growing Investment in Oncology Research Generates Demand for New Therapeutics
    • Regulatory Approvals for Novel Drugs Drives Adoption
    • Advancements in Molecular Diagnostics Sustains Growth of Colorectal Cancer Therapeutics
    • Expansion of Clinical Trials for Combination Therapies Drives Market Growth
    • Rising Healthcare Expenditure Strengthens Market Potential
    • Development of Biomarker-Based Therapies Expands Market Opportunities
    • Technological Advancements in Drug Delivery Systems Propel Market Growth
    • Growing Focus on Minimally Invasive Treatments Generates Demand for Innovative Therapies
    • Government Funding for Cancer Research Drives Development of New Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Colorectal Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Colorectal Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Colorectal Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Colorectal Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Colorectal Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Colorectal Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Gastrointestinal Carcinoid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Gastrointestinal Carcinoid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Gastrointestinal Carcinoid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • CHINA
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Colorectal Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Colorectal Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Colorectal Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Colorectal Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • INDIA
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Colorectal Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Colorectal Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Colorectal Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Colorectal Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Colorectal Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Colorectal Cancer Therapeutics by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Colorectal Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Colorectal Cancer Therapeutics by Cancer Type - Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Colorectal Cancer Therapeutics by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors and Other Cancer Types for the Years 2015, 2025 & 2030

IV. COMPETITION